Financing and Sustaining Medications for Opioid Use Disorder Programs in Jails and Prisons—Lessons From the Field
U.S. Food and Drug Administration-approved medications for opioid use disorder (methadone, buprenorphine, and naltrexone) as part of medication-assisted treatment (MAT) are the gold standard of care for people with opioid use disorders and should be offered in all correctional settings. However, jails face challenges in financing and sustaining correctional MAT programs, including securing leadership buy-in and support, overcoming reimbursement barriers, and understanding how to effectively negotiate provider contracts. Despite these challenges, a growing number of jails have successfully implemented and sustained MAT programs by leveraging financial and non-financial resources and strategies. In this webinar, four experts from the field discuss effective ways to finance and sustain correctional MAT programs.
- Shannon Mace, Senior Advisor, National Council for Mental Wellbeing
- Tyler Winkelman, Staff Physician, Hennepin County, Minnesota, Jail, Co-Director, Health, Homelessness, and Criminal Justice Lab at Hennepin Healthcare Research Institute
- Bruce Herdman, Chief of Medical Operations, Philadelphia, Pennsylvania, Department of Prisons
- Brandon George, Director, Indiana Addiction Issues Coalition Vice President of Recovery, Advocacy, and Programs, Mental Health America Indiana
- Nicole Banister, Policy Analyst, National Governors Association